Form 4: Pfizer CEO Albert Bourla Executes Stock Appreciation Rights, Adjusts Holdings
SEC Form 4 Filing
Pfizer's Chairman and CEO, Albert Bourla, executed stock appreciation rights and adjusted his holdings of Pfizer common stock on February 27, 2025.
Summary
- On February 27, 2025, Albert Bourla, Chairman & CEO of Pfizer Inc., executed stock appreciation rights, resulting in the acquisition of 582,823 shares of common stock at a price of $31.31.
- Following the transaction, Bourla directly owns 913,444 shares of common stock after withholding 18,300 shares at $26.1 to cover tax obligations and 545,855 shares at $26.06 to cover the exercise price.
- Bourla also indirectly owns 5,357 shares through a Rule 16b-3 plan.
- The execution of the stock appreciation rights involved the settlement based on the 20-day average closing price of Pfizer common stock ending on the settlement date.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it reflects standard executive compensation transactions. There is no indication of positive or negative implications for the company's performance or outlook.
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership, common among publicly traded companies. It provides transparency into the transactions of company insiders and their alignment with shareholder interests.
Comparison to Industry Standards
- Executive compensation packages often include stock options, restricted stock units, and stock appreciation rights to incentivize performance and align executive interests with shareholder value.
- The specific terms and conditions of these awards, such as vesting schedules and exercise prices, vary widely across companies and industries.
- Comparing Bourla's compensation structure and stock ownership to those of CEOs at comparable pharmaceutical companies (e.g., Johnson & Johnson, Merck, AbbVie) would provide a more comprehensive assessment of its competitiveness and alignment with industry norms.
Stakeholder Impact
- The transaction provides transparency to shareholders regarding executive compensation and alignment of interests.
- The filing has minimal direct impact on employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 02/27/2025 | Date of the earliest transaction: execution of stock appreciation rights and related transactions. |
| 03/03/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.